Challenges of meeting the future blood transfusion requirement in England and Wales. Autologous blood transfusion could become an adjunct to the UK blood transfusion program in the future

Transfusion Alternatives in Transfusion Medicine

Volumn 11, Issue 2, 2010, Pages 72-81

  Osaro, Erhabor ^a   Njemanze, Chima ^a  

^a BOLTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adjunct; Autologous; Transfusion; Transfusion program; UK

Indexed keywords

ERYTHROPOIETIN;

ACUTE NORMOVOLEMIC HEMODILUTION; ANEMIA; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD DONOR; BLOOD GROUP; BLOOD SALVAGE; BLOOD VOLUME; COST EFFECTIVENESS ANALYSIS; ELECTIVE SURGERY; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HEALTH CARE QUALITY; HEMODILUTION; HUMAN; MICROCIRCULATION; PERIOPERATIVE CELL SALVAGE; PERIOPERATIVE PERIOD; PREDEPOSIT AUTOLOGOUS DONATION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; THROMBOEMBOLISM; TISSUE PERFUSION; UNITED KINGDOM; VASCULARIZATION;

EID: 77954106266     PISSN: 12959022     EISSN: 1778428X     Source Type: Journal    
DOI: 10.1111/j.1778-428X.2010.01132.x     Document Type: Article

References (63)

1. McClelland B, Contreras M. Appropriateness and safety of blood transfusion. BMJ 2005, 330:104-5.
2. Murphy MF, Wallington TB, Kelsey P. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001, 113:24-31.
3. Claudia SC, Melissa MC. Oxygen therapeutics: perfluorocarbons and blood substitute safety. Crit Care Clin 2009, 25:399-414.
4. Riley W, Schwei M, McCullough J. The United States' potential blood donor pool: the prevalence of donor-exclusion factors on the pool of potential donors. Transfusion 2007, 47:1180-8.
5. Sullivan MT, Cotten R, Read EJ, Wallace EL. Blood collection and transfusion in the United States in 2001. Transfusion 2007, 47:385-94.
6. Whitaker BI, Sullivan M. The 2005 Nationwide Blood Collection and Utilization Survey Report. US Department of Health and Human Services
7. Leiby DA. Making sense of malaria. Transfusion 2007, 47:1573-7.
8. O'brien SF, Chiavetta JA, Goldman M. Predictive ability of sequential surveys in determining donor loss from increasingly stringent variant Creutzfeldt-Jakob disease deferral policies. Transfusion 2006, 46:461-8.
9. Busch MP, Wright DJ, Custer B. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerg Infect Dis 2006, 12:395-402.
10. Benefits and challenges of an aging population. Popul Trends 2008, 134:1. Office for National Statistics
11. Evandorou M, Falkingham J. Looking back to look forward: lessons from four birth cohorts for aging in the 21st century. Popul Trends 2000, 99:27-36.
12. Vamvakas EC, Taswell HF. Epidemiology of blood transfusion. Transfusion 1994, 34:464-70.
13. Wells AW, Mounter PJ, Chapman CE, Stainsby D, Wallis JP. Where does blood go? Prospective observational study of red cell transfusion in North England. BMJ 2002, 44:1447-52.
14. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: the Austrian benchmark study. Transfusion 2007, 47:1468-80.
15. Sullivan MT, Cotton R, Read EJ, Wallace EL. Blood collection and transfusion in the United States in 2001. Transfusion 2007, 47:366-8.
16. Blumberg N, Vanderlinde ES, Heal JM. Autologous transfusion. BMJ 2002, 324:772-5.
17. Sloand E, Kumar P, Klein HG, Merritt S, Sachser R. Transfusion of blood component to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994, 34:48-53.
18. Karger R, Kretschmer V. Modern concepts of autologous haemotherapy. Transfus Apher Sci 2005, 32:185-96.
19. Catling S, Williams S, Freites O. Use of a leucocyte filter to remove tumour cells from intra-operative cell salvaged blood. Anaesthesia 2008, 63:1332-8.
20. Blood Transfusion Therapy: A Physician's Handbook 1996, American Association of Blood Banks, 5th, edn., American Association of Blood Banks, Bethesda, MD
21. Goodnough LT. Autologous blood donation. Crit Care 2004, 8:S49-S52.
22. Lentschener C, Ozier Y. Acute normovolemic hemodilution: the subgroups of patients likely to benefit remains uncertain. Anaesthesiology 2002, 97:794-800.
23. Boulton FE, James V. Guidelines for policies on alternatives to allogeneic blood transfusion. 1. Predeposit autologous blood donation and transfusion. Transfus Med 2007, 17:354-65. British Committee for Standards in Haematology, Transfusion Task Force
24. Phillips SJ, Chavan R, Porter ML. Does salvaged and tranexamic acid reduce the need for blood transfusion in revision hip surgery. J Bone Joint Surg Br 2006, 88:1141-2.
25. Gonzalez-Porras JR, Colado E, Conde MP. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009, 19:35-42.
26. Lauder GR. Pre-operative predeposit autologous donation in children presenting for elective surgery: a review. Transfus Med 2007, 2:75-82.
27. Ono K, Shibata J, Tanaka T. Acute normovolemic hemodilution to reduce allogenic blood transfusion in patients undergoing radical cystectomy. Masui 2009, 58:160-4.
28. Kreimeier U, Messmer K. Hemodilution in clinical surgery: state of the art 1996. World J Surg 1996, 20:1208-17.
29. Gandhi SD, Weiskopf RB, Jungheinrich C. Volume replacement therapy during major orthopaedic surgery using Voluven (hydroxyethyl starch 130/0.4) or hetastarch. Anaesthesiology 2007, 106:1120-7.
30. Wolowczyk L, Lewis DR, Nevin M. The effect of acute normovolaemic haemodilution on blood transfusion requirements in abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2001, 22:361-4.
31. Sanders G, Mellor N, Rickards K. Prospective randomized controlled trial of acute normovolaemic haemodilution in major gastrointestinal surgery. Br J Anaesth 2004, 93:775-81.
32. McGill NA, O'Shaughnessy D, Herbertson MJ, Gill R. Acute normovolaemic haemodilution (ANH) is safe in patients with known coronary artery disease. Crit Care 2000, 4:4. doi:10.1186/cc706
33. Verma RR, Williamson JB, Dashti H, Patel D, Oxborrow NJ. Homologous blood transfusion is not required in surgery for adolescent idiopathic scoliosis. J Bone Joint Surg Br 2006, 88:1187-91.
34. Moxey AJ, O'Connell DL, Fergusson DA. Cell salvage for minimising perioperative allogenic blood transfusion. Cochrane Database Syst Rev 2003, (4). CD001888
35. Wang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg 2009, 109:320-30.
36. Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS. Intraoperative cell salvage during radical prostatectomy: a safe technique for Jehovah's Witnesses. Int Braz J Urol 2004, 30:377-9.
37. Nagarsheth NP, Sharma T, Shander A, Awan A. Blood salvage use in gynaecologic oncology. Transfusion 2009, 49:2048-53.
38. Guo XY, Luo AL, Duan H. Use of blood salvage machine in oncologic surgeries: a clinical observation of 13 cases. Zhonghua Yi Xue Za Zhi 2004, 84:107-10.
39. Hansen E, Bechmann V, Altmeppen J. Intraoperative blood salvage in cancer surgery: safe and effective? Transfus Apher Sci 2002, 27:153-7.
40. Wehner M, Konig F. Microbiological contamination of intraoperatively collected erythrocyte concentrates in mechanical auto transfusion in tumour surgery. Anaesthesiol Reanim 2001, 26:11-17.
41. Poli MC, Villa LL, Colella R, Deheinzelin D. Molecular evidence of tumour cell removal from salvaged blood after irradiation and leucocyte depletion. Transfus Med 2004, 14:151-5.
42. Kongsgaard UE, Wang MY, Kvalheim G. Leucocyte depletion filter removes cancer cells in human blood. Acta Anaesthesiol Scand 1996, 40:118-20.
43. Liang TB, Li DL, Liang L. Intraoperative blood salvage during liver transplantation in patients with hepatocellular carcinoma: efficiency of leukocyte depletion filters in the removal of tumour cells. Transplantation 2008, 85:863-9.
44. Poli M, Camargo A, Villa L. Intraoperative autologous blood recovery in prostate cancer surgery: in vivo validation using a tumour marker. Vox Sang 2008, 95:308-12.
45. Appraisal Consultation Document-Erythropoietin for anaemia induced by cancer treatment. 2005, NICE, National Institute for Health and Clinical Excellence
46. Ossa DF, Briggs A, McIntosh E. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics 2007, 25:223-37.
47. Davies L, Brown TJ, Haynes S. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006, 10:1-210.
48. Sonnenberg FA, Gregory P, Yomtovian R. The cost-effectiveness of autologous transfusion revisited: implications of an increased risk of bacterial infection with allogeneic transfusion. Transfusion 1999, 39:808-17.
49. Duffy G, Tolley K. Cost analysis of autologous blood transfusion, using cell salvage, compared with allogeneic blood transfusion. Transfus Med 1997, 7:189-96.
50. Vamvakas EC, Pineda AA. Autologous transfusion and other approaches to reduce allogenic blood exposures. Baillieres Best Pract Res Clin Haematol 2000, 97:794-800.
51. Murphy GJ, Rogers CS, Lansdowne WB. Safety, efficacy, and cost of intraoperative cell salvage and autotransfusion after off-pump coronary artery bypass surgery: a randomized trial. J Thorac Cardiovasc Surg 2005, 130:20-8.
52. Dramis A, Plewes J. Autologous blood transfusion after primary unilateral knee replacement surgery. Acta Orthop Belg 2006, 72:15-17.
53. Dietrich W. Autologous blood predonation in cardiac surgery. Transfus Clin Biol 2007, 14:526-9.
54. Amin A, Watson A, Mangwani J. A prospective randomised controlled trial of autologous retransfusion in total knee replacement. J Bone Joint Surg Br 2008, 90:451-4.
55. Wilson J, Yao GL, Raftery J. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007, 11:iii-iv.
56. Corwin HL, Gettinger A, Fabian TC. Efficacy and safety of epoetin alfa in clinically ill patient. N Engl J Med 2007, 357:965-76.
57. Groopman JE, Itri LM. Chemotherapy-induced anaemia in adults: incidence and treatment. J Natl Cancer Inst 1999, 91:1616-34. Review. Erratum in: 2000; :497
58. Bokemeyer C, Aapro MS, Courdi A. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007, 43:258-70. European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly
59. Rizzo JD, Lichtin AE, Woolf SH. American Society of haematology. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Haematology. J Clin Oncol 2002, 20:4083-107. American Society of Clinical Oncology
60. Remák E, Hutton J, Jones M, Zagari M. Changes in cost-effectiveness over time. The case of Epoetin Alfa for renal replacement therapy patients in the UK. Eur J Health Econ 2003, 4:115-21.
61. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004, 329:224-7.
62. Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR. Estimating the cost of blood; past, present and future directions. Best Pract Res Clin Anaesthesiol 2007, 21:271-9.
63. Beris P, Muñoz M, García-Erce JA. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008, 100:599-604.